MARKET

SNDX

SNDX

Syndax Pharmaceuticals Inc
NASDAQ
23.07
+1.63
+7.60%
After Hours: 23.52 +0.45 +1.95% 19:08 03/27 EDT
OPEN
21.79
PREV CLOSE
21.44
HIGH
23.26
LOW
21.69
VOLUME
1.19M
TURNOVER
0
52 WEEK HIGH
25.34
52 WEEK LOW
11.22
MARKET CAP
1.96B
P/E (TTM)
-7.7544
1D
5D
1M
3M
1Y
5Y
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Quanterix (QTRX)
TipRanks · 1d ago
Syndax Pharmaceuticals Price Target Maintained With a $41.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
Syndax Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Maintains $41 Price Target
Benzinga · 1d ago
Syndax Announces FDA Priority Review Of NDA For Revumenib For Treatment Of R/R KMT2Ar Acute Leukemia
NASDAQ · 1d ago
FDA grants priority review for Syndax leukemia drug, sets action date
Healthcare FDA grants priority review for Syndax leukemia drug, sets action date Mar. 26, 2024. The drug revumenib in the treatment of relapsed/refractory KMT2Ar acute leukemia. The FDA set a target action date of Sept. 26 for the application.
Seeking Alpha · 1d ago
Syndax Says Revumenib NDA Granted FDA Priority Review
Syndax Pharmaceuticals says FDA granted priority review to new drug application for revumenib for certain leukemia patients. The company says the drug is being reviewed under the FDA's real-time oncology review program. The drug is supported by positive data from a clinical trial, company says.
Dow Jones · 1d ago
Syndax Reports FDA Priority Review Of NDA For Revumenib For Treatment Of Relapsed/Refractory KMT2Ar Acute Leukemia
Benzinga · 1d ago
More
About SNDX
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. It is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Webull offers Syndax Pharmaceuticals Inc stock information, including NASDAQ: SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.